Amol Akhade: Real-World Evidence on HR+/HER2− mBC
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X about a recent article by Kripa Bajaj et al. published in Nature Scientific Reports:
“Real-world evidence from Tata Memorial In HR+/HER2− metastatic breast cancer, oral chemo-hormonal therapy (capecitabine + hormone therapy) showed encouraging outcomes in a heavily pre-treated cohort (median 3 prior lines):
Regimens:
Capecitabine + Tamoxifen / Letrozole / Exemestane / Fulvestrant
PFS: 8.8 mo | OS: 16.7 mo
Grade ≥3 toxicity: just 9.4% (mostly HFS)
Why it matters:
- Oral, low-cost, well-tolerated
- Practical option where newer agents aren’t accessible
- Capecitabine combos outperformed cyclophosphamide
This study highlights a promising, pragmatic strategy for MBC management. While retrospective, it sets the stage for future RCTs to formally evaluate these combinations.”
Title: Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer
Authors: Kripa Bajaj, Sushmita Rath, Deep Vora, Pallavi Parab, Seema Gulia, Swapnil Rane, Tanuja Shet, Jaya Ghosh, Palak Popat, Prabhat Bhargava, Anbarasan Sekar, Anuradha Mehta, Yogesh Kembhavi, Dinesh Jethwa, Rajiv Sarin, Tabassum Wadasadawala, Shalaka Joshi, Rajendra Badwe, Sudeep Gupta
Read the Full Article on Nature Scientific Reports
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023